As the panelists suggest methods to help control the costs of agents for the treatment of multiple sclerosis (MS) and improve patient care, Gary M. Owens, MD, explains that the US needs to aggressively review a drug’s cost versus its value and make products that do not provide outcomes sufficient to their costs more difficult for clinicians to access and treat patients with.
 
Dr Owens explains that because clinicians treat their MS patients at a population level, clinical guidelines are a necessity.
 
Leslie Fish, PharmD, agrees and believes that it is important that healthcare professionals receive clinical data about treatment effectiveness for certain patient populations.
 
Patricia K. Coyle, MD, suggests that improvements in MS disease activity biomarkers can also help clinicians make more educated decisions about treatment.
 

Episode 15 - Controlling Drug Prices and Working at the Population Level

During this segment, the panelists suggest methods to help control the costs of agents used to treat multiple sclerosis and improve patient care.
Published Online: January 03, 2014
As the panelists suggest methods to help control the costs of agents for the treatment of multiple sclerosis (MS) and improve patient care, Gary M. Owens, MD, explains that the US needs to aggressively review a drug’s cost versus its value and make products that do not provide outcomes sufficient to their costs more difficult for clinicians to access and treat patients with.
 
Dr Owens explains that because clinicians treat their MS patients at a population level, clinical guidelines are a necessity.
 
Leslie Fish, PharmD, agrees and believes that it is important that healthcare professionals receive clinical data about treatment effectiveness for certain patient populations.
 
Patricia K. Coyle, MD, suggests that improvements in MS disease activity biomarkers can also help clinicians make more educated decisions about treatment.
 
View More From This Discussion
Episode 1 Episode 1 - The Changing Tides of Multiple Sclerosis: Where Do We Currently Stand?
Episode 2 Episode 2 - Elucidating the Patient's Starting Point in Care
Episode 3 Episode 3- Exploring the Etiology of Multiple Sclerosis
Episode 4 Episode 4- Characterizing Multiple Sclerosis
Episode 5 Episode 5 - Elucidating the Economic Burden of MS
Episode 6 Episode 6 - Discussing the Pathophysiology of MS
Episode 7 Episode 7 - Increased Monetary Costs of Multiple Sclerosis
Episode 8 Episode 8 - Long-Term Effects of Disease-Modifying Therapies
Episode 9 Episode 9 - Exploring Trials, Data, and the Future of Multiple Sclerosis
Episode 10 Episode 10 - Treatment Complexities
Episode 11 Episode 11 - Clinical Guidelines Vital to the Future of MS
Episode 12 Episode 12 - New MS Agents Challenged
Episode 13 Episode 13 - Treatment Challenges for Progressive Disease
Episode 14 Episode 14 - Concerns about Rising Costs of Treatment
Episode 15 Episode 15 - Controlling Drug Prices and Working at the Population Level
Episode 16 Episode 16 - MRI Scans and MS
Episode 17 Episode 17 - Conclusion: Treatment Advancements and Final Remarks
right-arrow
Related Articles

More on AJMC.COM

$vacMongoViewPlus$